A Phase 2 interventional study of Liposomal Cyclosporine A and Liposomal Placebo in Bronchiolitis Obliterans Syndrome (BOS), GVHD, Chronic and Stem Cell Transplant Complications, sponsored by Zambon SpA. Terminated at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-03.
Sponsored by Zambon SpA · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Bronchiolitis Obliterans Syndrome with a site in France — 13 open to participants now, 17 under way, 5 of them phase 3. Bronchiolitis Obliterans Syndrome · France.
Among the 68 studies in Bronchiolitis Obliterans Syndrome with a site in France, this one is the 57th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2020, is one of 11 in phase 2, and was the 53rd registered.
714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.
Browse Bronchiolitis Obliterans Syndrome studies →13 of the 68 studies in Bronchiolitis Obliterans Syndrome with a site in France are open now. Recruiting first, the newest first:
Hopital Foch · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
Novartis Pharmaceuticals · Sites in France, United States, Australia and 14 more countries
Ages 1–18
Sanofi · Sites in France, United States, Belgium and 10 more countries
Ages 1–18
Enterra Medical, Inc. · Sites in France, United States, Belgium and 2 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 15 · Phase 3 27 · Phase 4 2
First in 2006; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.
Median enrollment 105 across the 58 interventional studies, 128 across the 10 observational. Of the 46 that completed or were terminated, 26 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 68 have an industry lead sponsor. The 10 most frequent:
Zambon SpA is the lead sponsor of 23 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Zambon SpA has 3 studies filed under Bronchiolitis Obliterans Syndrome — fewer than ten, so there is no comparison to draw.
6 of the studies in Bronchiolitis Obliterans Syndrome with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT06585774Phase 3Incyte CorporationA Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | 2027-09-28 |
| NCT05157685Phase 3Centre Hospitalier Intercommunal CreteilEvaluation of the Efficacy of Azithromycin in Idiopathic Purulent Oedematous Sinusitis in Adults | 2027-11-21 |
| NCT05685628Assistance Publique - Hôpitaux de ParisEvaluation of the Quality of Life Induced by the Cinnamon Anti-odor Dressing in Patients With Malodorous Wounds | 2027-04-19 |
| NCT07403500Centre Hospitalier Universitaire de NīmesEvaluation of the Short-term Effectiveness of Spinal Manipulation to Treat Acute and Subacute Low Back Pain. | 2027-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 68 studies in Bronchiolitis Obliterans Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
The primary objective of this study is to assess the tolerability and safety of two dose levels of aerosolized L-CsA vs placebo in addition to SoC therapy for BOS in adult allo-HSCT recipients.
Secondary Objectives:
The secondary objectives of this study are to assess PK and exploratory efficacy and quality of life of two dose levels of aerosolized L-CsA vs placebo in addition to SoC therapy for BOS in adult allo-HSCT recipients.
This is a Phase II prospective, multi-center, single-blind, randomized clinical trial evaluating safety and tolerability in adult recipients of an allo-HSCT with BOS. Twenty-four patients were planned for enrollment; but, at the time of the premature termination of this study, a total of 11 patients were screened for the study, of whom 5 patients did not fulfill the inclusion criteria and 6 patients were randomly allocated 1:1:1 in 3 treatment groups (L-CsA 10 mg + SoC, L-CsA 5 mg + SoC, or placebo + SoC).
A total of 18 centers in 3 countries (France, Germany, and Spain) in Europe were initiated for this multi-center study.
IMP was administered for up to 12 weeks treatment period. With low patient recruitment, the BOSTON-4 safety and tolerability study was terminated early by the sponsor on 18 March 2022. This decision was made after a careful and due diligent analysis performed by Zambon of the study status and considering the impact of coronavirus disease 2019 (COVID-19) pandemic on sites activities. From the beginning of the study, in December 2019, only 6 patients were randomized. So it was estimated that continuing the trial with the current protocol and setting would have taken another 9 years for the study to complete.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed diagnosis of BOS Score 1 [Jagasia et al. 2015] within > 6 months and \< 3 years after allo-HSCT:
/FVC \< 0.7 at Screening Visit AND Post-bronchodilator FEV1 >/= 60 and ≤ 79% predicted at Screening Visit AND
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Liposomal Cyclosporine A 10 mg (10 mg/2.5 mL) bid, once in the morning and once in the evening, for up to 12 weeks. The inhalations were scheduled to be taken approximately 12 hours (but not less than 6 hours) apart, eg, at 08:00 and 20:00 each day. Nebulization time per inhalation dose was approximately 8 to 13 minutes for the 0- and 10-mg doses. Standard of care included prophylaxis against common opportunistic infections, immunosuppression, and any other chronic medication
Drug: Liposomal Cyclosporine A
Liposomal Cyclosporine A 5 mg (5 mg/1.25 mL) bid, once in the morning and once in the evening, for up to 12 weeks. The inhalations were scheduled to be taken approximately 12 hours (but not less than 6 hours) apart, eg, at 08:00 and 20:00 each day. Nebulization time per inhalation dose was approximately 5 to 10 minutes for the 5-mg dose. Standard of care included prophylaxis against common opportunistic infections, immunosuppression, and any other chronic medication
Drug: Liposomal Cyclosporine A
Liposomal Placebo 2.5 mL (0 mg L-CsA/2.5 mL) bid, once in the morning and once in the evening, for up to 12 weeks. The inhalations were scheduled to be taken approximately 12 hours (but not less than 6 hours) apart, eg, at 08:00 and 20:00 each day. Nebulization time per inhalation dose was approximately 8 to 13 minutes for the 0- and 10-mg doses. Standard of care included prophylaxis against common opportunistic infections, immunosuppression, and any other chronic medication
Drug: Liposomal Placebo
Liposomal Cyclosporine A is administered at different dosages in the first two arms (10 mg bid and 5 mg bid, respectively) with a new technology of nebulizing liquid drugs, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Also known as: L-CsA
Liposomal Placebo is administered with the same new technology of nebulizing liquid drugs used for L-CsA, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Also known as: Placebo
Number of Local Tolerability Events of Interest From Baseline to Visit 3 (Week 4)
The local tolerability events of interest taken into consideration were: Cough, Wheezing, Bronchospasm, Throat irritation and Change from baseline in FEV1 to Visit 3.
Time frame: at Week 4 (visit 3)
Number of Participants With AE and sAE of Different Level of Severity During the First 4 Weeks of Treatment
An adverse event (AE) is any untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event is an adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.
Time frame: During the first 4 weeks of treatment
Number of Local Tolerability Events of Interest From Baseline to Week 12
The local tolerability events of interest taken into consideration were: Cough, Wheezing, Bronchospasm, Throat irritation and Change from baseline in FEV1 to Visit 3.
Time frame: at Week 12
Number of Participants With AE and sAE of Different Level of Severity During the First 12 Weeks of Treatment
An adverse event (AE) is any untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event is an adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.
Time frame: During the first 12 weeks of treatment
CsA Whole Blood Concentrations and CsA Whole Blood Trough Levels
Whole Blood concentrations (Week 0) are at pre-dose, directly after end of inhalation, 15, 30, and 45 minutes, and 1, 1.5, 2, and 4 hours after end of inhalation, and whole blood trough levels (CsA concentration) at Weeks 2, 4, 8, and 12 were calculated.
Time frame: Weeks 0 (pre-dose, directly after end of inhalation, 15, 30, 45, 60 min, 1.5 h, 2h, 4h), 2, 4, 8, and 12
From the start of the trial, only 6 patients were randomized. With low patient recruitment, the BOSTON-4 safety and tolerability study was terminated early on 18 March 2022. This decision was made after a careful and due diligent analysis performed by Zambon of the study status and considering the impact of coronavirus disease 2019 (COVID-19) pandemic on sites activities. So, due to this low recruitment, the Sponsor decided to early terminate the trial, on 18 March 2022.
| Milestone | L-CsA 10 mg Plus Standard of Care | L-CsA 5 mg Plus Standard of Care | Liposomal Placebo Plus Standard of Care |
|---|---|---|---|
| Started | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 |
The local tolerability events of interest taken into consideration were: Cough, Wheezing, Bronchospasm, Throat irritation and Change from baseline in FEV1 to Visit 3.
| number of local events | L-CsA 10 mg Plus Standard of Care | L-CsA 5 mg Plus Standard of Care | Liposomal Placebo Plus Standard of Care |
|---|---|---|---|
| Any Local Tolerability Event | 1 | 5 | 4 |
| Cough | 0 | 1 | 1 |
| Wheezing | 0 | 0 | 0 |
| Bronchospasm | 0 | 0 | 0 |
| Throat irritation | 1 | 3 | 2 |
| Change in FEV1 | 0 | 1 | 1 |
An adverse event (AE) is any untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event is an adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.
| Participants | L-CsA 10 mg Plus Standard of Care | L-CsA 5 mg Plus Standard of Care | Liposomal Placebo Plus Standard of Care |
|---|---|---|---|
| Any TEAEs | 1 | 1 | 1 |
| Mild TEAEs | 1 | 1 | 1 |
| Moderate TEAEs | 0 | 0 | 0 |
| Severe TEAEs | 0 | 0 | 0 |
| Serious TEAEs | 0 | 0 | 0 |
| Related TEAEs | 1 | 1 | 1 |
| COVID-19 related TEAEs | 0 | 0 | 0 |
| Patients discontinued study due to TEAEs | 0 | 0 | 0 |
| Patients discontinued treatment due to TEAEs | 0 | 0 | 0 |
| TEAEs Leading to Death | 0 | 0 | 0 |
The local tolerability events of interest taken into consideration were: Cough, Wheezing, Bronchospasm, Throat irritation and Change from baseline in FEV1 to Visit 3.
| number of events | L-CsA 10 mg Plus Standard of Care | L-CsA 5 mg Plus Standard of Care | Liposomal Placebo Plus Standard of Care |
|---|---|---|---|
| Any Local Tolerability Event | 1 | 7 | 6 |
| Cough | 0 | 2 | 2 |
| Wheezing | 0 | 0 | 0 |
| Bronchospasm | 0 | 0 | 0 |
| Throat irritation | 1 | 4 | 3 |
| Change in FEV1 | 0 | 1 | 1 |
An adverse event (AE) is any untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event is an adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.
| Participants | L-CsA 10 mg Plus Standard of Care | L-CsA 5 mg Plus Standard of Care | Liposomal Placebo Plus Standard of Care |
|---|---|---|---|
| Any TEAEs | 2 | 1 | 1 |
| Mild TEAEs | 2 | 1 | 1 |
| Moderate TEAEs | 1 | 0 | 0 |
| Severe TEAEs | 0 | 0 | 0 |
| Serious TEAEs | 1 | 0 | 0 |
| Related TEAEs | 1 | 1 | 1 |
| COVID-19 related TEAEs | 0 | 0 | 0 |
| Patients discontinued study due to TEAEs | 0 | 0 | 0 |
| Patients discontinued treatment due to TEAEs | 1 | 0 | 0 |
| TEAEs Leading to Death | 0 | 0 | 0 |
Whole Blood concentrations (Week 0) are at pre-dose, directly after end of inhalation, 15, 30, and 45 minutes, and 1, 1.5, 2, and 4 hours after end of inhalation, and whole blood trough levels (CsA concentration) at Weeks 2, 4, 8, and 12 were calculated.
| ng/ml | L-CsA 10 mg Plus Standard of Care | L-CsA 5 mg Plus Standard of Care | Liposomal Placebo Plus Standard of Care |
|---|---|---|---|
| Week 0 - predose | 12.2115 ± 17.26967 | 0.0000 ± 0.0000 | 11.7750 ± 16.65236 |
| Directly after end of inhalation | 84.6510 ± 69.82821 | 19.3420 ± 15.91980 | 12.1760 ± 17.21946 |
| 15 min | 73.5110 ± 59.82123 | 30.0500 ± 24.34003 | 11.2440 ± 15.90142 |
| 30 min | 68.3640 ± 60.56228 | 26.9400 ± 22.19184 | 13.1780 ± 18.63651 |
| 45 min | 70.1555 ± 64.88483 | 23.2780 ± 18.52761 | 13.3145 ± 18.82955 |
| 1 hour | 117.8030 ± NA | 19.4395 ± 18.15638 | 14.0835 ± 19.91708 |
| 1.5 hours | 115.4350 ± NA | 16.0300 ± 13.34876 | 13.0425 ± 18.44488 |
| 2 hours | 67.0700 ± 71.46587 | 13.4045 ± 10.80530 | 10.9615 ± 15.50190 |
| 4 hours | 33.3425 ± 35.73506 | 8.3950 ± 8.09920 | 7.6615 ± 10.83500 |
| Whole Blood Trough Levels - Week 2 | 48.6725 ± 64.65148 | 4.6365 ± 3.62534 | 6.0500 ± 8.55599 |
| Whole Blood Trough Levels - Week 4 | 16.2465 ± 17.33048 | 16.8475 ± 21.28745 | 6.3000 ± 8.90955 |
| Whole Blood Trough Levels - Week 8 | 18.7280 ± 26.48539 | 9.0405 ± 3.16855 | 4.9500 ± 7.00036 |
| Whole Blood Trough Levels - Week 12 | 23.0195 ± 32.55449 | 0.0000 ± NA | 4.9500 ± 7.00036 |
Collected over Throughout the complete clinical trial period, i.e. up to week 14 (visit 6 / EoS).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| L-CsA 10 mg Plus Standard of Care | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| L-CsA 5 mg Plus Standard of Care | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Liposomal Placebo Plus Standard of Care | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Event | L-CsA 10 mg Plus Standard of Care | L-CsA 5 mg Plus Standard of Care | Liposomal Placebo Plus Standard of Care |
|---|---|---|---|
| moderate acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/2 | 0/2 | 0/2 |
| Event | L-CsA 10 mg Plus Standard of Care | L-CsA 5 mg Plus Standard of Care | Liposomal Placebo Plus Standard of Care |
|---|---|---|---|
| Throat irritationRespiratory, thoracic and mediastinal disorders | 1/2 | 1/2 | 1/2 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/2 | 1/2 | 1/2 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 0/2 | 1/2 | 0/2 |
| WheezingRespiratory, thoracic and mediastinal disorders | 1/2 | 0/2 | 0/2 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/2 | 0/2 | 0/2 |
The Safety Analysis Set (SAF) was defined as all randomized patients who had received a partial dose of IMP at least once.
| Age, Categorical(Participants) | L-CsA 10 mg Plus Standard of Care | L-CsA 5 mg Plus Standard of Care | Liposomal Placebo Plus Standard of Care | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 2 | 2 | 6 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | L-CsA 10 mg Plus Standard of Care | L-CsA 5 mg Plus Standard of Care | Liposomal Placebo Plus Standard of Care | Total |
|---|---|---|---|---|
| Mean | 55.5 ± 0.71 | 63.0 ± 0.00 | 46.0 ± 12.73 | 54.8 ± 9.52 |
| Sex: Female, Male(Participants) | L-CsA 10 mg Plus Standard of Care | L-CsA 5 mg Plus Standard of Care | Liposomal Placebo Plus Standard of Care | Total |
|---|---|---|---|---|
| Female | 0 | 2 | 1 | 3 |
| Male | 2 | 0 | 1 | 3 |
| Ethnicity (NIH/OMB)(Participants) | L-CsA 10 mg Plus Standard of Care | L-CsA 5 mg Plus Standard of Care | Liposomal Placebo Plus Standard of Care | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 2 |
| Not Hispanic or Latino | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 2 | 1 | 0 | 3 |
| Region of Enrollment(participants) | L-CsA 10 mg Plus Standard of Care | L-CsA 5 mg Plus Standard of Care | Liposomal Placebo Plus Standard of Care | Total |
|---|---|---|---|---|
| France | 1 | 1 | 0 | 2 |
| Germany | 1 | 0 | 1 | 2 |
| Spain | 0 | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2020 to primary completion in Jun 2022, 28 months.
Results were first posted in Oct 2023, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine
Bronchiolitis Obliterans Syndrome →